Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial

IMPORTANCE: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated that tucatinib in combination with trastuzumab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Nancy U., Murthy, Rashmi K., Abramson, Vandana, Anders, Carey, Bachelot, Thomas, Bedard, Philippe L., Borges, Virginia, Cameron, David, Carey, Lisa A., Chien, A. Jo, Curigliano, Giuseppe, DiGiovanna, Michael P., Gelmon, Karen, Hortobagyi, Gabriel, Hurvitz, Sara A., Krop, Ian, Loi, Sherene, Loibl, Sibylle, Mueller, Volkmar, Oliveira, Mafalda, Paplomata, Elisavet, Pegram, Mark, Slamon, Dennis, Zelnak, Amelia, Ramos, Jorge, Feng, Wentao, Winer, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716438/
https://www.ncbi.nlm.nih.gov/pubmed/36454580
http://dx.doi.org/10.1001/jamaoncol.2022.5610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716438/
https://www.ncbi.nlm.nih.gov/pubmed/36454580
http://dx.doi.org/10.1001/jamaoncol.2022.5610

Ejemplares similares